Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients.

Objective: To determine the influence of nevirapine (NVP) and lopinavir/ritonavir (LPV/r) on the efficacy of pegylated interferon (peg-IFN) plus ribavirin (RBV) among HIV/HCV-coinfected patients. Methods: All HIV/HCV-coinfected patients who received peg-IFN plus RBV while under a three-drug antiretroviral regimen including tenofovir (TDF) plus lamivudine (3TC) or emtricitabine (FTC) along with NVP or along with LPV/r at twenty hospitals in Spain were included in this retrospective study. Sustained virological response (SVR) rates in both groups were compared. Results: A total of 165 patients were included in the study, 71 (43%) receiving NVP and 94 (57%) LPV/r. Significantly more patients on LPV/r had a baseline HCV-RNA load ≥600000 IU/mL (44% vs. 73%, p=0.001). Forty (56%) individuals included in the NVP group and 35 (37%) in the LPV/r group showed SVR (p=0.015). In the NVP group, 19 (43%) patients carrying genotype 1-4 and 21 (78%) subjects with genotype 2-3 achieved SVR. In the LPV/r group, the corresponding figures were 25% (p=0.04) and 59% (p=0.1). In the subpopulation of individuals with baseline HCV viral load ≥600,000 IU/mL, 18 (58%) of those taking NVP vs. 21 (31%) who were given LPV/r reached SVR (p=0.01). HCV genotype 2-3, adherence to HCV therapy >80% and use of NVP during peg-IFN plus RBV were independently associated with SVR in the multivariate analysis. Conclusions: HIV/HCV-coinfected patients who receive NVP respond better to peg-IFN plus RBV than those individuals receiving LPV/r. Lower HCV viral load due to NVP treatment may account for the former differences.

[1]  M. L. de la Mata,et al.  Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin , 2009, Hepatology.

[2]  A. Mocroft,et al.  Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy , 2009, AIDS.

[3]  F. Carrat,et al.  Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV–hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study , 2009, Antiviral therapy.

[4]  D. Podzamczer,et al.  Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. , 2009, Journal of acquired immune deficiency syndromes.

[5]  Ming‐Lung Yu,et al.  Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. , 2009, Journal of hepatology.

[6]  J. Macías,et al.  Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. , 2009, Journal of hepatology.

[7]  S. Petta,et al.  Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. , 2009, Journal of hepatology.

[8]  C. Tural,et al.  Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients , 2009, Hepatology.

[9]  C. Tural,et al.  Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. , 2008, The Journal of antimicrobial chemotherapy.

[10]  V. Soriano,et al.  Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir , 2008, Antiviral therapy.

[11]  Wenyu Lin,et al.  HIV increases HCV replication in a TGF-beta1-dependent manner. , 2008, Gastroenterology.

[12]  R. Bruno,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults , 2008, HIV medicine.

[13]  C. Tural,et al.  Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection , 2007, AIDS.

[14]  F. Carrat,et al.  High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART? , 2007, AIDS.

[15]  J. Pineda,et al.  Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. , 2007, The Journal of antimicrobial chemotherapy.

[16]  H. Conjeevaram,et al.  Race, insulin resistance and hepatic steatosis in chronic hepatitis C , 2007, Hepatology.

[17]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[18]  J. Macías,et al.  Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C , 2005, Antiviral therapy.

[19]  F. Carrat,et al.  Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy , 2005, Journal of acquired immune deficiency syndromes.

[20]  B. Clotet,et al.  Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response , 2005, Antiviral therapy.

[21]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[22]  K. Yarasheski,et al.  Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.

[23]  V. Soriano,et al.  Weight loss in HIV-infected patients. , 2002, The New England journal of medicine.

[24]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[25]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[26]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[27]  C. Winkler,et al.  Relation Between HIV‐1 and Hepatitis C Viral Load in Patients With Hemophilia , 2001, Journal of acquired immune deficiency syndromes.

[28]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[29]  Panel de expertos del Grupo de Estudio de Sida Spain,et al.  [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. , 2010, Enfermedades infecciosas y microbiologia clinica.

[30]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.